{
    "clinical_study": {
        "@rank": "105840", 
        "acronym": "CDNISLongterm", 
        "arm_group": [
            {
                "arm_group_label": "Subjects na\u00efve to botulinum toxin A (BoNT-A) treatment", 
                "description": "Patients na\u00efve to botulinum toxin A treatment"
            }, 
            {
                "arm_group_label": "Subjects pre-treated with botulinum toxin A (BoNT-A) injection", 
                "description": "Patients pre-treated with botulinum toxin A for at least 2 years.\n4 injection cycles, each at 3 to 4 months intervals. Investigators follow their individual injection protocol for the treatment with BoNT-A (modalities of administration in accordance with local Summary of Product Characteristics)."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to investigate the efficacy of Dysport\u00ae in the treatment of\n      cervical dystonia (CD) in a non-interventional long-term study in na\u00efve and pre-treated\n      patients."
        }, 
        "brief_title": "Longitudinal Study for Treatment With Botulinum Toxin A Injections in na\u00efve and Pre-treated Patients Suffering From Cervical Dystonia [CD-NIS-Longterm]", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Cervical Dystonia", 
        "condition_browse": {
            "mesh_term": [
                "Dystonia", 
                "Dystonic Disorders", 
                "Stress, Psychological", 
                "Torticollis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Suffering from cervical dystonia with rotational torticollis/-caput or\n             laterocollis/-caput as the primary component\n\n          -  Na\u00efve to botulinum toxin A or pre-treated with botulinum toxin A on a regular basis\n             for at least 2 years prior to inclusion and last injection with Dysport\u00ae and last\n             injection between 3 and 6 months prior to inclusion\n\n          -  With the intention to be treated with Dysport\u00ae\n\n        Exclusion Criteria:\n\n          -  The subject has already been included in this study\n\n          -  Participation in an interventional trial\n\n          -  Suffering from anterocollis or retrocollis as primary component"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients suffering from cervical dystonia"
            }
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01840462", 
            "org_study_id": "A-94-52120-165"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 22, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wiesbaden", 
                        "country": "Germany"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Germany"
            ]
        }, 
        "number_of_groups": "2", 
        "official_title": "A National, Multicenter, Non-interventional, Prospective, Longitudinal Study for Treatment With Botulinum Toxin A Injections in na\u00efve and Pre-treated Patients Suffering From Cervical Dystonia (Dysport\u00ae)", 
        "overall_contact": {
            "email": "clinical.trials@ipsen.com", 
            "last_name": "Ipsen Recruitment Enquiries"
        }, 
        "overall_official": {
            "affiliation": "Ipsen", 
            "last_name": "Andrea Reissig, PhD.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Austria: Agency for Health and Food Safety"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The Tsui rating scale is a disease-specific score to evaluate the severity of CD taking the clinical signs of CD into account in a standardised manner.", 
            "measure": "Change in Tsui scores", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 12 weeks post-injection Cycle 2"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01840462"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The Tsui rating scale is a disease-specific score to evaluate the severity of CD taking the clinical signs of CD into account in a standardised manner.", 
                "measure": "Change in Tsui scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 12 weeks post-injection Cycle 1"
            }, 
            {
                "description": "The Tsui rating scale is a disease-specific score to evaluate the severity of CD taking the clinical signs of CD into account in a standardised manner.", 
                "measure": "Change in Tsui scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 12 weeks post-injection Cycle 3"
            }, 
            {
                "description": "The Tsui rating scale is a disease-specific score to evaluate the severity of CD taking the clinical signs of CD into account in a standardised manner.", 
                "measure": "Change in Tsui scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 12 weeks post-injection Cycle 4"
            }
        ], 
        "source": "Ipsen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ipsen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}